Manufacturing
-
Andrew Harnik via Getty Images
US, EU agree to terms of framework trade pact
The countries documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, pharmaceuticals and semiconductors.
By Philip Neuffer • Aug. 21, 2025 -
Alamy
Pharma reshoringAbbVie to build API plant in Illinois as it steps up US production
The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.
By Kristin Jensen • Aug. 13, 2025 -
Anna Moneymaker via Getty Images
Trump administrationWith FDA PreCheck, drugmakers may get a manufacturing boost
The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in the U.S.
By Amy Baxter • Aug. 13, 2025 -
Anna Moneymaker via Getty Images
Pharma reshoring
Trump threatens up to 250% tariffs on pharma imports
The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the next year and a half.
By Philip Neuffer • Aug. 5, 2025 -
Permission granted by Mirus Bio LLC
Sponsored by Mirus Bio LLCThe race to scale to 1,000 liters and beyond in gene therapy manufacturing
Extend transfection complex formation time by up to 3 hours, reduce complex volume by >50% and maintain high titers and full capsids.
Aug. 4, 2025 -
Anna Moneymaker via Getty Images
US to install country-specific tariffs Aug. 7
An executive order President Trump signed Thursday codifies rates for over 60 trading partners, including Switzerland. A probe into pharmaceuticals that’s expected to result in sectoral tariffs remains ongoing.
By Philip Neuffer • July 31, 2025 -
Permission granted by AstraZeneca
Pharma reshoringAstraZeneca grows US presence with $50B in spending plans
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as well as R&D investment.
By Ned Pagliarulo • July 21, 2025 -
Permission granted by MilliporeSigma
Sponsored by MilliporeSigmaFrom bench to batch: AAV manufacturing for the next-generation of gene therapies
Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.
July 21, 2025 -
XH4D via Getty Images
Private equity firms back PCI Pharma in bet on drug production
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.
By Ben Fidler • July 14, 2025 -
Courtesy of National Resilience; Business Wire
National Resilience, a well-funded manufacturing startup, to scale back operations
The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”
By Gwendolyn Wu • June 10, 2025 -
Permission granted by Resilience
Sponsored by ResilienceNavigating the evolving landscape of fill/finish: Challenges and what’s ahead
The demand for fill/finish services has never been greater, how are CDMOs responding?
May 27, 2025 -
aprott via Getty Images
Obesity drugsNovo pressures GLP-1 compounders as FDA ban takes hold
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.
By Kristin Jensen • May 22, 2025 -
Permission granted by West Pharmaceutical Services
Sponsored by West Pharmaceutical ServicesHow regulatory convergence is raising the bar for sterile drug safety—and how West leads the way
Global regulators continue to raise the bar on sterile drug manufacturing—and West is responding.
May 19, 2025 -
Permission granted by PHIL
Sponsored by PHILBridging the data gaps that impact retail and specialty-lite success
Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.
May 19, 2025 -
Courtesy of Sanofi
Pharma reshoringSanofi to pour more than $20B into US drug research and manufacturing
The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could change amid shifting Trump administration policies.
By Kristin Jensen • May 15, 2025 -
Justin Sullivan via Getty Images
Pharma reshoringGilead, bracing for tariffs, joins peers in US drug production push
The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and operational investments in U.S. drug manufacturing.
By Kristin Jensen • May 8, 2025 -
Anna Moneymaker via Getty Images
Trump orders FDA to help speed building of new drug factories
Yet regulatory relief for U.S. expansion could be accompanied by new tariffs and drug pricing rules.
By Jonathan Gardner • May 6, 2025 -
Anna Moneymaker via Getty Images
Pharma reshoringPharma downplays tariff threat, even as risks remain unclear
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.
By Ned Pagliarulo , Jonathan Gardner • May 1, 2025 -
Chip Somodevilla via Getty Images
Merck takes $200M tariff hit, trimming its gross profits
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
By Jonathan Gardner • April 24, 2025 -
Sedat Suna via Getty Images
Pharma reshoringRoche, answering tariff threat, pledges $50B to US drug production
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S., among them a gene therapy plant in Pennsylvania.
By Jonathan Gardner • April 22, 2025 -
Win McNamee via Getty Images
Trump administrationUS launches probe that could set stage for pharma tariffs
The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.
By Ned Pagliarulo • Updated April 14, 2025 -
Veronique D via Getty Images
Pharma reshoringAmid tariff turmoil, Novartis commits to spending $23B on US manufacturing
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
By Jonathan Gardner • April 10, 2025 -
Anna Moneymaker / Staff via Getty Images
Trump administrationTrump pauses most reciprocal tariffs, hikes China’s further
Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the broader market.
By Philip Neuffer • April 9, 2025 -
Chip Somodevilla via Getty Images
Trump administrationMedtech industry pressures White House to exempt devices from tariffs
AdvaMed and other healthcare groups have pleaded for the Trump administration to exempt medical devices and critical supplies.
By Ricky Zipp • April 8, 2025 -
Bevan Goldswain via Getty Images
Tariffs send healthcare industry into ‘unchartered waters’
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.
By Susanna Vogel • April 4, 2025
